INDEX

Page numbers in **boldface** type indicate major discussions. Letters after page numbers refer to the following: c = case study; f = figure; r = reference; t = table.

A

AAN (American Academy of Neurology), 600, 652, 685
practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710

Absence epilepsy, 581t
antiepileptic drugs for, 645, 647
classification and characterization of, 593t
EEG in, 674t
self-limited, 594
treatment choices for, 674t–675t
dietary therapy for, 759, 765r
early-onset, 579t, 589t
juvenile, 575, 587t, 590, 591f
EEG in, 674t
treatment choices for, 674t–675t
myoclonic, 578, 581t, 587t, 591f
with perioral myoclonia, 606c
triggered by phenobarbital, 645

Acetazolamide
for catamenial epilepsy, 699
use in children, 662t–663t

A-plexus (NA), 600, 652, 685
practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710

Adenylsuccinate lyase deficiency, 579t

Adrenocorticotropic hormone (ACTH)
efficacy compared with ketogenic diet, 762, 766r
for infantile spasms, 577c, 679
use in children, 662t–663t

Adolescent-onset epilepsies, 588t, 590

AEDs. See Antiepileptic drugs

AES (American Epilepsy Society), practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710

American Academy of Neurology (AAN), 600, 652, 685
practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710

American Epilepsy Society (AES), practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710

American Society of Human Genetics, 796

γ-Aminobutyric acid (GABA), 599

Amiodarone, interaction with antiepileptic drugs, 652

Amobarbital, 734

Amygdalohippocampectomy, 735

Anti-NMDA receptor antibody encephalitis, 592c–593c, 592f, 596r, 597r

Antiarhythmic drugs, interaction with antiepileptic drugs, 652

Antidepressants
for anxiety disorders, 691
for depression, 689–690
interaction with antiepileptic drugs, 652

Antiepileptic drugs (AEDs), 643–654, 654r–655r.
See also specific drugs
for absence seizures, 645, 647
in children, 593t, 660c
adverse effects of, 645, 646t
in children, 663t, 665t, 669t, 671t, 672
depression, 652, 689, 690c
documenting discussions with patients about, 802, 803r
with drug combinations, 648–649, 649t, 672–673
documenting discussions with patients at risk for, 672
idopathic reactions, 804
impact on health-related quality of life, 693
monitoring for, 801–804, 801c, 804f–805f
osteoeprosta/osteoporosis, 652
psychosis, 691
suicidalty, 688–689
teratogenicity, 652, 653c, 702, 703–707, 703t
weight gain, 650

in benign epilepsy with centrotemporal spikes, 593t
during breast-feeding, 684–685, 694r, 705c
brief-spectrum, 645, 647, 648t
for children, 660–673, 680r–681r
in absence epilepsy, 593t, 660c
adherence to, 673
adjusting medications based on seizure timing, 672
cognitive effects of, 684–685
discontinuation of, 673
dosing of, 663t, 665t, 667t, 669t, 671t
goals of, 661
indications for, 660–661
medication selection and management of, 661, 662t–671t
polypharmacy and drug interactions with, 672–673
side effects and monitoring of, 663t, 665t, 667t, 669t, 671t
tracking response to, 672
cognitive effects of, 683–685
in adults, 683–684
in children, 684–685
in unborn child, 685, 686c
continuation after epilepsy surgery, 740
discontinuation of, 650, 673
dosage of, 784t, 786t, 788t
in Dravet syndrome, 593t
drug interactions with, 652, 654r, 672–673
efficacy and tolerability of, 643, 648
in epilepsy with hypothalamic hamartoma, 593t
hypersensitivity to, 650
for infantile spasms, 577c
in epilepsy with hypothalamic hamartoma, 593t
hypersensitivity to, 650
for juvenile myoclonic epilepsy, 647c
mechanisms of action and metabolism of,
644t
mechanisms of action of, 784t, 786t, 788t
mood-stabilizing effects of, 652
narrow-spectrum, 645, 648t
for patients with specific health issues, 650,
652, 778
chronic illness, 652
obesity, 650
psychiatric disorders, 652
renal or hepatic disease, 650, 652
pharmacokinetics of, 785t, 787t, 789t
in pregnancy, 652
Y 653, 653c, 655r, 702–711, 713r, 714r
neonatal complications of, 708–709
neurodevelopmental effects of, 685, 686c,
69r, 707–708, 709f
pharmacokinetics of, 709–711, 710t
fetal teratogenicity of, 652, 653c, 702, 703–707, 709t
monotherapies, 703–706, 705c, 706f, 707t
polytherapy, 706–707
resistance to, 595, 730–731, 743–744
response to, 595
selection of, 643–650
for children, 661, 662t–671t
determining adequate number of drugs, 650,
651c
for elderly people, 653–654
by epilepsy syndrome, 645, 647
for initial therapy, 647–648
use of add-on drugs, 648–650, 649t
standard of care and use of, 802
in status epilepticus, 770, 775c, 781t, 783f,
784t–789t, 793c–794r
for diagnosis of nonconvulsive status
epilepticus, 770, 777t
use in women, 652–653
in West syndrome, 593t
Antifungals, interaction with antiepileptic drugs,
652
Antipsychotics, 692c
interaction with antiepileptic drugs, 652
for psychosis, 691
Antiretroviral agents, interaction with antiepileptic drugs, 652
Anxiety disorders, 691, 696r
antiepileptic drug-induced, 652
depression and, 691, 726
impact on health-related quality of life, 693
psychogenic nonepileptic events or episodes
and, 726
Arteriovenous malformations, 579t, 737
Astrocytoma, resection of, 736
Atomic seizures, 581t, 584t
Auras, 585t
Autoimmune encephalopathies, 600
Autoimmune/inflammatory processes, 573, 580r,
587t
Automatisms, 585t, 627c
Autonomic ictal features, 585t
Autosomal dominant epilepsy with auditory
features (autosomal dominant lateral temporal
lobe epilepsy), 579t, 587t
Autosomal dominant nocturnal frontal lobe
epilepsy, 579t, 587t
Azathioprine, 679

B
Balloon cells, in focal cortical dysplasias, 631, 633t
Barbiturates. See also specific drugs
adverse effects of, 646t
cognitive effects of, 684
Beck Depression Inventory, 687, 688, 689, 752
Benign epilepsy with centrotemporal spikes, 587t,
588, 591f
classification and characterization of, 593t
EEG in, 600, 605f
Benign familial infantile epilepsy, 586t, 591f
Benign familial neonatal epilepsy, 579t, 586t,
589, 591f
Benign infantile epilepsy, 586t
Benign neonatal seizures, 588t
Benign Rolandic epilepsy
EEG in, 605f, 674t
treatment choices for, 674t–675t
Benzodiazepines, 692c. See also specific drugs
adverse effects of, 785t
for anxiety disorders, 691
as broad-spectrum agents, 648t
cognitive effects of, 684
mechanism of action of, 784t
pharmacokinetics of, 785t
for psychosis, 691
in status epilepticus, 770c, 776–778, 781t, 783f,
784t–787t
for diagnosis of nonconvulsive status
epilepticus, 777t
use in children, 662t–665t
Bilaterally independent periodic lateralizing
discharges (BIPLDs) on EEG, 613, 613t, 614f
Birth defects, antiepileptic drug-induced, 652,
654r, 702, 705–707, 703t
monotherapies, 703–706, 705c, 706f, 707t
polytherapy, 706–707
Bone mineral density, antiepileptic drug effects
on, 652, 711–712, 711c, 714r

863
Brain abscess, 580t
Brain neoplasms
antineoplastic drugs for patients with, 778
epilepsy due to, 579t, 580t, 587t
neuroimaging of, 637–638, 637f–639f, 639t
resection of, 736–737, 736f
status epilepticus due to, 769t
Brainstem mechanisms, 573–574
Breast-feeding and antiepileptic drugs, 684–685,
694r, 705c
Breath-holding spells, 715
Bromides
adverse effects of, 646t
mechanism of action and metabolism of, 644t
Bupropion, 600, 690
Buspirone, 691
C
Calcium channel blockers, interaction with
antiepileptic drugs, 652
Carbamazepine, 606c, 692c
adverse effects of, 646t, 802, 804
hematologic effects, 804
HLA-B*1502 allele and risk for
Stevens-Johnson syndrome, 672, 804, 805r
weight gain, 650
during breast-feeding, 685
cognitive effects of, 684, 693r
combined with other antiepileptic drugs, 649
lacosamide, 649
lamotrigine, 649, 649t
drug interactions with, 652
efficacy of, 648
for epilepsy with hippocampal sclerosis, 627c
hypersensitivity to, 650
indications for, 647
mechanism of action and metabolism of, 644t
mood-stabilizing effects of, 652
as narrow-spectrum agent, 645, 648t
in pregnancy, 652, 685, 704, 705c
neurodevelopmental effects of, 707, 708, 709f
pharmacokinetics of, 710, 710t
teratogenicity of, 652, 704, 705c, 706–707, 706f, 707f
use in children, 662t–663t
Cardiac arrest, treatment of refractory and
myoclonic status epilepticus after, 791
Cardiac disease, 579t
Cardiac malformations, antiepileptic
drug–induced, 652, 703, 705t, 704, 706
Case studies
absence seizures with perioral myoclonia,
606c–607c
anti-NMDA receptor antibody encephalitis,
592c–593c
antiepileptic drug effects on bone mineral
density, 711c
antiepileptic drugs in pregnancy, 653c, 686c,
705c–706c
childhood absence epilepsy, 660c
convulsive status epilepticus, 770c
diagnostic coding, 803c–812c
dietary therapies, 761c
Dravet syndrome, 576c
epileptic seizures and neurocardiogenic
syncope, 615c–618c
ethics of genetic testing in children with
epilepsy, 795c
infantile spasms, 577c
leviracetam in juvenile myoclonic epilepsy,
647c
mesial temporal lobe epilepsy and
hippocampal sclerosis, 627c
monitoring and antiepileptic drug safety, 801c
mood effects of antiepileptic drugs, 690c
nonconvulsive status epilepticus, 775c
diagnosis in critically ill patient, 778c
psychogenic nonepileptic events or episodes,
721c
psychosis and epilepsy, 692c
surgical treatment
contraindications to, 732c
for focal cortical dysplasia, 738c–739c
in mesial temporal epilepsy, 736c
use of multiple antiepileptic drugs, 651c
vagus nerve stimulation, 747c
Catamenial epilepsy, 697–700, 712f
criteria for, 698
definition of, 697
patterns of, 698, 699f
treatment options for, 698–700
Cataplexy, 715
Cavernous malformations, 579t, 737
CDC (Centers for Disease Control and
Prevention), 796
Cefepime, EEG abnormalities induced by, 600
Center for Epidemiologic Study Depression
Screen, 688, 689
Center for Medicare and Medicaid Services
(CMS), 806
Centers for Disease Control and Prevention
(CDC), 790
Cephalic auras, 585t
Cerebral infarction, 579t
Cerebrovascular disease, 579t
Chanelopathies, 573, 574, 579t
Chemotherapeutic agents, interaction with
antiepileptic drugs, 652
Childbirth rates, 701–702
Childhood epilepsy, 586t–587t, 656–680,
680r–681r
absence epilepsy, 575, 587t, 588, 591f, 593t,
660c
classification and characterization of, 593t
EEG in, 674t
self-limited, 594

treatment choices for, 674t–675t
antiepileptic drug therapy for, 660–673
adherence to, 673
adjusting medications based on seizure timing, 672
cognitive effects of, 684–685
discontinuation of, 673
dosing of, 663t, 665t, 667t, 669t, 671t
goals of, 661
indications for, 660–661
medication selection and management of, 661, 662t–671t
polypharmacy and drug interactions with, 672–673
side effects and monitoring of, 663t, 665t, 667t, 669t, 671t, 672
in specific epilepsy syndromes, 674t–675t
tracking response to, 672
chances of seizure recurrence in, 660–661
diagnostic evaluation of, 656
chances of seizure recurrence in, 660

diagnostic targets for, 578–594
epilepsies and epilepsy diagnosis, 580–594, 586t–589t
etiology, 578, 579t–580t
seizure types, 578–580, 581t, 582t, 583f, 584t–586t
goals of, 571
history of, 571–572
meaning of, 572
as organizational system, 572
updated terminology and concept for, 571, 573–576
epileptic encephalopathy, 594
etiologies/causes, 571, 573, 574t
mode of onset and presentation, 571, 573–576, 575t
pharmacoresponsive or pharmacoresistant epilepsy, 595
self-limited epilepsy, 594–595
Cleft lip/palate, antiepileptic drug–induced, 652, 705, 703t, 704, 706
Clonazepam for catamenial epilepsy, 699
use in children, 662t–663t
Clonazepam, 692c
teratogenicity of, 707t
use in children, 662t–663t
Clonic seizures, 581t, 584t
Clozapine, EEG abnormalities induced by, 600
CMS (Center for Medicare and Medicaid Services), 806
Vitamin C deficiency, 579f
Coding, diagnostic,
Cognitive impairment in epilepsy, 682–687, 695–694t, 730
antiepileptic drugs and, 683–685
in adults, 683–684
in children, 684–685
in unborn child, 685, 686c, 707–708
before first seizure, 682
neuropsychological and pathologic substrates of, 682–683
psychosocial factors and, 687
seizure effects and, 683
temporal lobe epilepsy surgery and, 685–686, 732
vagus nerve stimulation and, 686–687
Computed tomography (CT), 624
of low-grade tumors, 638f, 639f
in status epilepticus, 774, 775f, 780t
in tuberous sclerosis, 638
Congenital malformations, antiepileptic drug–induced, 652, 654t, 702, 703–707, 703t
monotherapies, 703–706, 705c, 706f, 707t
polytherapy, 706–707
Contraception, 702, 714t
Conversion disorder, 722–723, 725
Corpus callosotomy, 738–739
Cortical development, malformations of, 579t, 587t, 596f
neuroimaging of, 623, 631–637, 641t–642r
focal cortical dysplasias, 623, 625, 628t, 629f, 630, 630f, 631–632, 632f, 633t
hemimegalencephaly, 636f, 637
lissencephaly/agyria-pachygyria, 635f, 636
periventricular nodular heterotopia, 635f, 636, 636f
polymicrogyria, 634–636, 634f, 635f
schizencephaly, 653–654, 654f
subcortical laminar heterotopia, 635f, 636
Corticosteroids, 679, 681r
Counseling, genetic, 578, 797–799, 799r–800r
CPT (Current Procedural Terminology) codes, 807–808
useful internet tips for coding, 808
CT. See Computed tomography
useful internet tips for coding, 808
Cyclophosphamide, 679

D

Dacrystic seizures, 585t
Deep brain stimulation of anterior nucleus of thalamus, 743, 746–749, 754r
advantages and disadvantages of, 753
adverse effects of, 749
cognitive effects of, 687, 749
efficacy of, 749
evidence for, 747
multicenter randomized controlled trial of, 748–749
procedure for, 747–748, 748f
responder rate for, 752
Dentatorubral-pallidoluysian atrophy, 579t
Depression, 687–691, 694r–696r
antiepileptic drug-induced, 652, 689, 690c, 804
anxiety disorders and, 691, 726
features and incidence in epilepsy, 687–688
impact on health-related quality of life, 692–693
interictal dysphoric disorder and, 689
preictal, ictal, and postictal, 689
psychogenic nonepileptic spells and, 688
risk factors for, 687
screening tests for, 688, 689
subsyndromic, 689
suicide risk and, 688–689
treatment of, 689–691
antidepressants, 689–690

cognitive behavioral therapy, 690–691

electroconvulsive therapy, 690

gymnastics and undertiagnosis and undertreatment of, 688
vagus nerve stimulation for, 745
Depth electrodes, intracranial, 620
Diagnosis of epilepsy, 580–594, 586t–589t
by adult neurologists, 588
by age at initial presentation, 580, 586t–587t
in children, 656
nonepileptic paroxysmal events mimicking epileptic seizures, 658t–659t
seizure confirmation, 656–657, 660c
vs. classification, 571, 572
EEG in, 598, 600–602, 620r–622r
correlation with clinical history and imaging studies, 602
normal variants or benign patterns that may confuse diagnosis, 607–608, 609t, 610f
with photic stimulation or hyperventilation, 601, 602f
sensitivity and specificity of, 600–601, 601f
with sleep deprivation, 601
sources of error, 602
electroclinical syndromes, 582
nonsyndromic epilepsies, 589t, 590–591, 591f, 594
seizure types and, 578–580, 581t, 582t, 583f, 584r–586t
Diagnostic and Statistical Manual of Mental Disorders (DSM), 689, 722–723
Diagnostic coding, 806–809, 809c–812c, 812r
Diaperam, 692c
adverse effects of, 785t
dosage of, 784t
pharmacokinetics of, 785t
for status epilepticus, 776, 781t, 784t–785t
use in children, 664r–665t
Dietary therapies, 756–765, 765r–766r
compared with normal American diet, 758–759, 759t
composition by percentage of kilocalories, 759t
contraindications to, 763–764
dropout rates from, 762–763
history of, 756–757
indications for, 679, 759–760, 761c
ketogenic diet, 678–679, 756–757
low glycemic index treatment, 757, 758, 758t
medium-chain triglyceride diet, 756, 757
modified Atkins diet, 757–758
outcomes of, 760–763
overview of, 757–759
potential mechanisms of action of, 759, 760f
requirements for, 758t
side effects of, 763, 765t
monitoring and management of, 764
in status epilepticus, 790t
trends and future direction of, 764
websites for information on, 765
Diffusion tensor imaging and tractography, 639–640, 642r
Digoxin, interaction with antiepileptic drugs, 652
Discontinuation of antiepileptic drug therapy, 650, 673
Doose syndrome, 573, 576c, 576f, 579t, 586t, 588, 591f, 594
classification and characterization of, 593t
dietary therapy for, 679, 759
EEG in, 576f, 609t, 674t
gene therapy, 576c, 589t
pharmacoresistance of, 593t, 595
treatment choices for, 674–675t
Driving, 647, 687, 709, 724, 803t
Drug interactions with antiepileptic drugs, 652, 654r, 672–673
Drug intoxication, status epilepticus due to, 769t
Drug-resistant epilepsy, 595, 730–731, 743–744, 754r
dietary treatment of, 756–765, 765r–766r
neurostimulation for, 743–754, 754r–755r
surgery for, 730–740, 740r–742r, 743–744
DSM (Diagnostic and Statistical Manual of
Mental Disorders), 689, 722–723
Dual-energy x-ray absorptiometry (DXA), 711
DXA (dual-energy x-ray absorptiometry), 711
Dyscognitive events, 585t
Dysembryoplastic neuroepithelial tumors, 579t
neuroimaging of, 638, 639t
resection of, 736
Dystonia, 715

EEG. See Electroencephalography
Elderly people
antiepileptic drugs for, 653–654, 655r
cognitive effects of, 684
status epilepticus in, 767
Electroconvulsive therapy
for depression, 690
for status epilepticus, 790t
Electroencephalography (EEG), 598–620,
620r–622r
abnormal epileptic patterns on, 604–607
in epileptic encephalopathies, 607, 609r
cognitive, 607, 609r
focal spikes or sharp waves, 604–605, 605f
generalized spikes, 605–607, 606c–607c, 606f
rhythmic temporal delta activity, 607, 608f
slow spike and wave, 607
in absence epilepsy
childhood, 674t
juvenile, 674t
with perioral myoclonia, 606c–607c, 606f
ambulatory, 619
in anti-NMDA receptor antibody encephalitis,
592c, 592f
in autoimmune encephalopathies, 600
in benign epilepsy with centrotemporal spikes,
600
in benign rolandic epilepsy, 605f, 674t
continuous EEG monitoring in the ICU, 613,
618–619
in diagnosis of epilepsy, 598, 600–602
correlation with clinical history and imaging
studies, 602
with photic stimulation or hyperventilation,
601, 602f
sensitivity and specificity of, 600–601, 601f
with sleep deprivation, 601
sources of error, 602
in Dravet syndrome, 576f, 609t, 674t
drug-induced abnormalities on, 600
in epileptic seizures and neurocardiogenic
syncpe, 616f–618f
in epileptic spasms, 582t, 583f
infantile, 577c, 577f
history of, 598
in juvenile myoclonic epilepsy, 601f, 674t, 686c
in Landau-Kleffner syndrome, 674t
in Lennox-Gastaut syndrome, 674t
in metabolic disorders, 600
in myoclonic seizures, 582t, 583f
in myoclonic-tonic seizures, 582t, 583f
nonspecific abnormal nonepileptic patterns on,
602–604, 603t
diffuse slow activity, 602
focal slow activity, 602
focal voltage attenuation, 602
frontal intermittent rhythmic delta activity,
602, 603f, 604
triphasic waves, 602, 604, 604f
normal, in epilepsy, 600
normal variants or benign patterns on,
607–608, 609t, 610f–612f
14 and 6 positive spikes, 608
rhythmic midtemporal theta of drowsiness,
607–608
6-Hz spike and wave, 608
subclinical rhythmic electrographic
discharges of adults, 608
wicket spikes, 607, 608
in Dravet syndrome, 576f, 609t, 609t
in Ohtahara syndrome, 607, 609t, 674t
in Panayiotopoulos syndrome, 674t
physiologic basis for interictal patterns on,
598–600, 599f
in preoperative workup, 731, 733f, 734, 739f
for childhood epilepsy, 676, 676f
psychogenic nonepileptic seizures on, 619–620
in status epilepticus, 608–613, 773–774
continuous EEG monitoring, 618, 622r, 768,
774, 778c, 779f
convulsive, Mycoplasma
pneumoniae–associated, 771f
nonconvulsive, 775f
periodic patterns, 609, 613t, 614f–615f
progressive sequence of changes, 608–609,
621r
in tonic seizures, 582t, 583t
utility of inpatient video-EEG monitoring,
619–620 (see also Video-EEG monitoring)
invasive monitoring, 620
scalp EEG monitoring, 619–620
in West syndrome, 603t, 607, 609t, 674t
Electromyography (EMG)
in epileptic spasms, 582t
in myoclonic seizures, 582t
in myoclonic-tonic seizures, 582t
in tonic seizures, 582t
Encephalitis, 580t
anti-NMDA receptor antibody, 592c–593c, 592f
Encephalopathy(ies)
autoimmune, 600
epileptic, 594
with continuous spike-and-wave during
sleep, 587t
EEG in, 607, 609t
immunomodulatory therapies for, 679
Hashimoto, 600
hypoxic-ischemic, 579t, 587t
mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes, 579t
myoclonic, 586t
toxic-metabolic, 603t
Epigastric auras, 585t, 627c
Epilepsy
antiepileptic drugs for, 643–654, 654r–655r
childhood, 586r–587t, 565–680, 680r–681r
cognitive impairment in, 682–687, 693r–694r, 730
diagnosis of, 580–594, 586t–589t
diagnostic coding for, 806–809, 809c–812c, 812r
differentiating nonepileptic behavioral disorders from, 715–727, 727r–729r
drug-resistant, 595, 730–731, 743–744, 754r
dietary treatment of, 756–765, 765r–766r
neurostimulation for, 743–754, 754r–755r
surgical treatment of, 730–740, 740r–742r, 743–744
EEG in, 598–620, 620r–622r
mortality and, 730
neuroimaging in, 623–641, 641r–642r
pharmacoresponsive or pharmacoresistant, 595
psychiatric disorders and, 687–691, 694r–696r
self-limited, 594–595
in women, 697–712, 712r–714r
Epilepsy of infancy with migrating focal seizures, 586t
Epilepsy with generalized tonic-clonic seizures alone, 587t
Epileptic encephalopathy, 594
with continuous spike-and-wave during sleep, 587t
EEG in, 607, 609t
immunomodulatory therapies for, 679
Epileptic spasms, 578, 581t, 584t, 596r
differential diagnosis of, 582r
EEG in, 577c, 577t, 582t, 583f
infantile, 577c, 577t, 578, 596r (see also West syndrome)
adrenocorticotropic hormone for, 577c, 679
dietary therapy for, 679, 759
due to tuberous sclerosis, vigabatrin for, 645
Episodic ataxia types 1 and 2, 579t
Etidrocarbazepine, 648t
Estrogens
interactions between epilepsy, antiepileptic drugs and, 697, 698f
during menstrual cycle, 698, 699f
during perimenopausal transition, 700
Ethosuximide
for absence seizures, 645
in children, 660c
adverse effects of, 646t
mechanism of action and metabolism of, 644t
as narrow-spectrum agent, 648t
pharmacokinetics in pregnancy, 710x
use in children, 660c, 664t–665t
Etiologies/causes of epilepsy, 578, 579r–580t
generic, 571, 573, 574t, 579t
structural-metabolic, 571, 573, 574t
unknown, 571, 573, 574t
updated terminology and concepts for, 571, 573, 574t
Etomidate
adverse effects of, 787t
dosage of, 786t
pharmacokinetics of, 787t
for status epilepticus, 786–787t
European and International Registry of Antiepileptic Drugs in Pregnancy (EURAP), 705c
European Federation of Neurological Societies, 772
European Surveillance of Congenital Anomalies (EUROCAT), 704
Eyelid myoclonia, 578, 581t
Ezogabine
adverse effects of, 646t
weight gain, 650
indications for, 647
mechanism of action and metabolism of, 645t
spectrum of activity of, 648t
use in children, 664t–665t

F
Factitious disorders, 722–723
Familial focal epilepsy with variable foci, 587t
Febrile infection–related epilepsy syndrome (FIRES), ketogenic diet for, 679
Febrile seizures, 586t, 588t, 594
generalized epilepsy with, 579t, 589t, 596r
status epilepticus due to, 769t
Felbamate
adverse effects of, 646t
as broad-spectrum agent, 645, 648t
dosage of, 788t
in hepatic disease, 650
mechanism of action and metabolism of, 644t
pharmacokinetics of, 789t
for status epilepticus, 788–789t
use in children, 664t–665t
Fertility, 700, 701–702.
See also Pregnancy
Fetal effects of maternal seizures, 709
FIRES (frontal intermittent rhythmic delta activity) on EEG, 602, 603f, 603t, 604
FIRES (febrile infection–related epilepsy syndrome), ketogenic diet for, 679
Focal cortical dysplasia, 577c, 641r, 731
balloon cells in, 631, 633t
neuroimaging of, 623, 625, 628t, 629f, 630, 630f, 631–632, 632f, 633t, 731
surgery for, 737, 737f–739f, 738c–739c
Focal seizures, 571, 573–576, 575t, 578, 581t
Folic acid-stimulating hormone (FSH), 700
Fosphenytoin
adverse effects of, 785t
dosage of, 784t
pharmacokinetics of, 785t
for status epilepticus, 778, 781t, 783f, 784t
presurgical imaging evaluation of, 628, 631t
Hippocampal resection, 735
presurgical imaging evaluation of, 628, 631t
Hypothalamic hamartoma with epilepsy, 579t, 593t
gelastic seizures, 587t, 588, 590f
surgical treatment of, 737
vagus nerve stimulation and, 678
Hypothalamic hypogonadism, 700
Hypothalamic-pituitary-ovarian axis, 697, 698f
Hypothermia, for status epilepticus, 790t
Hypoxic-ischemic encephalopathy, 579t, 587t
Hyprrrhythmia, infantile spasms with, 577c, 577f, 607
ICD. See International Classification of Diseases
ICD (interictal dysphoric disorder), 689
IDDI (Interictal Dysphoric Disorder Inventory), 689
ILAE (International League Against Epilepsy), 571, 572, 595r, 596r, 600, 619, 657, 807
Immune therapies
for childhood epilepsy, 679
for status epilepticus, 788c–789c, 790
Immunosuppressive agents, interaction with antiepileptic drugs, 652
Infantile epilepsies, 571, 573–576, 575t, 578, 581t
Dravet syndrome, 573, 576, 576c, 576f
specific genes first associated with one epilepsy syndrome then found to be associated with a different epilepsy syndrome, 589t
Genetic testing in children with epilepsy, 795–799, 795c, 799–800r
ACCE model for decision making about, 796
diagnostic, 796–797
Genetic counseling before, 797–799
Gestural seizures, 585t
Glions, 579t, 637f–638f, 638
Glucose transporter type 1 (GLUT1) deficiency syndrome, 579t, 589t, 596r, 679
dietary therapy for, 678–679, 759
Gonadotropin-releasing hormone (GnRH), 700
GPDs (generalized periodic discharges) on EEG, 613, 613t, 615f
H
Hallucinations, 692c, 735
Hashimoto encephalopathy, 600
Hemiconvulsions, 576c, 578
Hemimegalencephaly, 636f, 637, 738
Hemispherectomy, 737, 738
Hemispheric syndromes, 738
Hepatic disease, antiepileptic drugs in, 650, 652, 778
Hippocampal resection, 735
Hippocampal sclerosis
mesial temporal lobe epilepsy with, 587t, 625f, 626f, 627c, 627t, 628, 631t
presurgical imaging evaluation of, 628, 631t
Hippocampi, 756, 765r
HIV infection, 580t
HLA-B*1502 allele and risk for Stevens-Johnson syndrome, 672, 804, 805r
Hormonal contraceptives, interaction with antiepileptic drugs, 652, 702
HRQOL. See Quality of life, health-related
Hyperekplexia, 573–574, 586t, 596r
Hyperkinetic/hypermotor seizures, 585t
Hyperventilation, EEG with, 601, 621r
Hypomotor/behavioral arrest seizures, 584t
Hypoplasias, antiepileptic drug-induced, 704, 706
Hypothalamic hamartoma with epilepsy, 579t, 593t
gelastic seizures, 587t, 588, 590f
surgical treatment of, 737
vagus nerve stimulation and, 678
Hypothalamic hypogonadism, 700
Hypothalamic-pituitary-ovarian axis, 697, 698f
Hypothermia, for status epilepticus, 790t
Hypoxic-ischemic encephalopathy, 579t, 587t
Hypsarrhythmia, infantile spasms with, 577c, 577f, 607
GABA (γ-aminobutyric acid), 599
Gabapentin, 692c
adverse effects of, 646t, 787t
teratogenicity, 707t
weight gain, 650
cognitive effects of, 684, 693r, 694r
dosage of, 786t
efficacy of, 648
hypersensitivity to, 650
mechanism of action and metabolism of, 645, 648t
pharmacokinetics of, 787t
in renal disease, 650
for status epilepticus, 786t–787t
use in children, 664t–665t
Gangliogliomas, 579t
neuroimaging of, 637f, 638
resection of, 736, 736f
Gaucher disease, 579t
Gelastic seizures with hypothalamic hamartoma, 587t, 588, 590f
Generalized periodic discharges (GPDs) on EEG, 613, 613t, 615f
Generalized seizures, 571, 573–576, 575t, 578, 581t
Genetic epilepsies, 571, 573, 574t, 576, 578, 579t, 596r
Dravet syndrome, 573, 576, 576c, 576f
specific genes first associated with one epilepsy syndrome then found to be associated with a different epilepsy syndrome, 589t
Genetic testing in children with epilepsy, 795–799, 795c, 799–800r
ACCE model for decision making about, 796
diagnostic, 796–797
genetic counseling before, 797–799
Gestural seizures, 585t
Glions, 579t, 637f–638f, 638
Glucose transporter type 1 (GLUT1) deficiency syndrome, 579t, 589t, 596r, 679
dietary therapy for, 678–679, 759
Copyright © American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Infantile spasms, 577c, 577f, 578, 596r. See also West syndrome
adrenocorticotropic hormone for, 577c, 679
dietary therapy for, 679, 759
due to tuberous sclerosis, vigabatrin for, 645
Infectious etiologies of epilepsy, 580t, 587t
status epilepticus due to, 769t, 770c
Infertility, 700, 701–702
Informed consent, 802
Insomnia, antiepileptic drug-induced, 652
Interictal dysphoric disorder (IDD), 689
Interictal Dysphoric Disorder Inventory (IDDI), 689
International Classification of Diseases (ICD), 571, 572, 723
diagnostic code set, 806
International League Against Epilepsy (ILAE), 571, 572, 595r, 596r, 600, 619, 657, 807
Intracranial depth electrodes, 620
Intrauterine device (IUD), 702
Intravenous immunoglobulin
for childhood epilepsy, 679
for status epilepticus, 788t, 789t
IUD (intrauterine device), 702
Juvenile absence epilepsy, 575, 587t, 590, 591f
EEG in, 674t
Treatment choices for, 674t–675t
Juvenile myoclonic epilepsy, 575, 579t, 587t, 590, 591f
EEG in, 601f, 674t, 686c
levetiracetam for, 647c
outcome of, 594–595, 597r
pharmacoresponsiveness of, 595
treatment choices for, 674t–675t
KCNQ2 gene mutations, 589t, 596r
Kemla Registry of Epilepsy and Pregnancy, 701
Ketamine
adverse effects of, 787t
dosage of, 786t
pharmacokinetics of, 787t
for status epilepticus, 770c, 786t–787t, 790
Ketogenic diet, 678–679, 756–765, 765r–766r
composition by percentage of kilocalories, 759r
contraindications to, 763–764
efficacy of, 762
fats in, 757
history of, 756–757 (See also Dietary therapies)
indications for, 679, 759–760, 761c
initiation of, 757
overview of, 757
potential mechanisms of action of, 759, 760f
requirements for, 758t
side effects of, 763, 763t
monitoring and management of, 764
for status epilepticus, 790t
trends and future direction of, 764
vagus nerve stimulation and, 759
websites for information on, 765
Krabbe disease, 579t
Laboratory testing in status epilepticus, 772–773, 780t
Lacosamide
adverse effects of, 646t, 785t
combined with other antiepileptic drugs, 649
dosage of, 784t
indications for, 647
mechanism of action and metabolism of, 645t
pharmacokinetics of, 785t
spectrum of activity of, 648t
for status epilepticus, 778, 782, 784t–785t
Drug trial for diagnosis of nonconvulsive status epilepticus, 777t
use in children, 664–665t
Laffey body disease, 579t
Lamotrigine, 606c, 692c, 801c
adverse effects of, 646t
anxiety or insomnia, 652
during breast-feeding, 685
as broad-spectrum agent, 645, 648t
cognitive effects of, 684
combined with other antiepileptic drugs, 649
lacosamide, 649
tabproza, 649, 694t, 653c
efficacy and tolerability of, 643, 648
indications for, 645, 647, 647c
mechanism of action and metabolism of, 644t
mood-stabilizing effects of, 652
for patients with specific health issues, 650
in pregnancy, 652, 653c, 655t, 685, 704, 705c, 714r
neurodevelopmental effects of, 708, 709f
pharmacokinetics of, 710–711, 710t
teratogenicity of, 652, 704t, 705c, 706, 706f, 707t
use in children, 666–667t
Landau-Kleffner syndrome, 587t, 591f, 594
EEG in, 607, 609t, 674t
immunomodulatory therapies for, 679
treatment choices for, 674t–675t
vagus nerve stimulation, 678
Leigh syndrome, 579t
Lennox-Gastaut syndrome, 576, 579t, 587t, 594
EEG in, 603t, 609t, 674t
treatment choices for, 674t–675t
dietary therapy, 579
rufinamide, 645
vagus nerve stimulation, 678
worsening by phenobarbital, 645
Levetiracetam, 606c
adverse effects of, 646t, 785t, 804
behavioral effects, 652
psychosis, 691
during breast-feeding, 705c
as broad-spectrum agent, 645, 648t
cognitive effects of, 684
dosage of, 784t
efficacy and tolerability of, 643, 648
hypersensitivity to, 650
indications for, 645
in juvenile myoclonic epilepsy, 647c
mechanism of action and metabolism of, 644t
pharmacokinetics of, 785t
in pregnancy, 705c
pharmacokinetics of, 710, 710t
teratogenicity of, 707t
in renal disease, 650
for status epilepticus, 770c, 778, 781t, 782
784t–785t
drug trial for diagnosis of nonconvulsive
status epilepticus, 777t
use in children, 666t–667t
Levonorgestrel intrauterine device, 702
LH (luteinizing hormone), 700
Lidocaine
adverse effects of, 787t
dosage of, 786t
pharmacokinetics of, 787t
for status epilepticus, 786t–787t
Lipid-lowering agents, interaction with
antiepileptic drugs, 652
Lissencephaly, 579t
Lissencephaly-agryria-pachygyria, 635f, 636
Lithium, EEG abnormalities induced by, 600
Lorazepam
adverse effects of, 785t
dosage of, 784t
pharmacokinetics of, 785t
for status epilepticus, 770c, 775c, 776–777,
781t, 783f, 784t–785t
use in children, 666t–667t
Low glycemic index treatment, 757, 758t
composition by percentage of kilocalories, 759t
efficacy of, 762
overview of, 758
sample diet for, 758t
Lumbar puncture, 776, 780t
Luteinizing hormone (LH), 700

M
Magnesium sulfate
adverse effects of, 789t
dosage of, 788t
pharmacokinetics of, 789t
for status epilepticus, 788t–789t
Magnetic resonance imaging (MRI), 597r, 623,
624–626, 641r–642r
in anti-NMDA receptor antibody encephalitis,
592f
of deep brain stimulation lead placement, 748f
in Dravet syndrome, 576c
functional, for localization of seizure focus, 735
in gelastic seizures with hypothalamic
hamartoma, 590f
indications for, 624
in infantile spasms, 577c, 577f
of low-grade tumors, 637f–639f
in malformations of cortical development,
631–637
focal cortical dysplasias, 623, 625, 628t, 629f,
630, 630f, 631–632, 632f, 633t, 731, 738f
hemimegalencephaly, 635f, 637
lissencephaly-agryria-pachygyria, 635f, 636
periventricular nodular heterotopia, 635f,
636, 636f
polymicrogyria, 634–636, 634f, 635f
schizencephaly, 633–634, 634f
subcortical laminar heterotopia, 635f, 636
in mesial temporal lobe epilepsy, 625, 626,
626–628
with hippocampal sclerosis, 625f, 626f, 627c,
627t, 628, 631t, 642r
of mesial temporal sclerosis, 736c, 736f
in neocortical epilepsies, 623, 625, 628–631,
628t, 629f, 630f
normal, identifying seizure focus in patients
with, 731, 732c
in pharmacoresistant epilepsy with focal sei-
zures arising from left temporal lobe, 590f
in preoperative workup, 731
for childhood epilepsy, 676, 676f
protocols for, 623, 624–626, 629f, 630f
in Rasmussen encephalitis, 590f, 624, 639
in status epilepticus, 774, 780t
in temporal lobe epilepsy, 683
in tuberous sclerosis, 637–638, 637f
volumetric, of cognitive function, 683
Magnetic resonance spectroscopy (MRS), 623,
640, 642r
of hippocampal sclerosis, 631t
in mesial temporal lobe epilepsy, 640
Magnetoencephalography (MEG), 676
Major depressive disorder (MDD). See Depression
Malaria, 580t
Malingering, 722
Mammalian target of rapamycin (mTOR), 578
Medium-chain triglyceride diet, 756, 757.
See also Dietary therapies
Medroxyprogesterone acetate
for catamenial epilepsy, 699
intramuscular, for contraception, 702
MEG (magnetoencephalography), 676
Memory deficits. See Cognitive impairment
Meningioma, 579t, 736
Meningitis, 580t
Meningitis, 579t, 736
Meningitis, 580t
Menopause, 700
Menstrual cycle–related epilepsy, 697–700. See
also Catamenial epilepsy
Mental retardation, 623
epilepsy in females with, 576, 586t, 589t, 595
Mesial temporal lobe epilepsy, 588
familial, 597r
with hippocampal sclerosis, 587t, 625f, 626f, 627c, 627t
magnetic resonance spectroscopy in, 640
with mesial temporal sclerosis, 735, 736c
MRI in, 623, 625, 626f, 627c, 627t
positron emission tomography in, 640
single-photon emission computed tomography in, 641
surgical treatment of, 730, 735, 736c
Mesial temporal lobe epilepsy (MTLE), 588
familial, 597r
with hippocampal sclerosis, 587t, 625f, 626f, 627c, 627t
presurgical imaging evaluation of, 628
magnetic resonance spectroscopy in, 640
MRI in, 623, 625, 626f, 627c, 627t
positron emission tomography in, 640
single-photon emission computed tomography in, 640
Mesial temporal sclerosis (MTS), 735, 736c, 738
Metabolic disorders
EEG in, 600
status epilepticus due to, 769t
Methsuximide, use in children, 666t, 667t
Methylprednisolone, for status epilepticus, 788t, 789t
Midazolam
adverse effects of, 785t, 787t
dosage of, 784t, 786t
pharmacokinetics of, 785t, 787t
for status epilepticus, 647c, 647c
levetiracetam for, 645, 647c
outcome of, 594–595, 597r
pharmacoresponsiveness of, 595
treatment choices for, 674t–675t
levetiracetam for, 645, 647c
progressive, 579t, 587t
EEG in, 607, 609t
with ragged red fibers, 579t
worsening by phenobarbital, 645
Myoclonic seizures, 581t, 584t
differential diagnosis of, 582t
EEG in, 582t, 583f
negative, 584t
Myoclonic status epilepticus after cardiac arrest, 791
Myoclonic-tonic seizures, 578, 581t
EEG in, 582t, 583f
positive, 584t
Mysoline, depression induced by, 652

N
NAA (N-acetylaspartate), 580
National Birth Defects Prevention Study, 704
National Center for Health Statistics, 808
NCS (Neurocritical Care Society), 767, 772, 774, 783, 789
NEAD (Neurodevelopmental Effects of Antiepileptic Drugs) study, 708
Neocortical epilepsies
neuroimaging in, 623, 625, 628–630, 628t
surgical treatment of, 735–736
Neonatal complications of in utero exposure to antiepileptic drugs, 708–709
Neonatal epilepsy, 586t
Neonatal seizures, 579t, 580t, 587t
See also Brain neoplasms
status epilepticus due to, 769t
Neurocritical Care Society (NCS), 767, 772, 774, 783, 789
Neurocysticercosis, 580t
Neurocardiogenic syncope, 615c–618c, 616f–618f
Neurocritical Care Society (NCS), 707, 772, 774, 783, 789
Neurocysticercosis, 580t
Neurodevelopmental effects of antiepileptic drugs, 685, 686c, 694r, 707–708, 709f, 713r–714r
Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study, 708
Neuroimaging, 623–641, 641r–642r. See also specific imaging modalities
CT, 624
diffusion tensor imaging and tractography, 639–640, 642r
emergent, 624
indications for, 624
of low-grade tumors, 637f–639f, 638
magnetic resonance spectroscopy, 640
in mesial temporal lobe epilepsy with hippocampal sclerosis, 623, 625, 625f, 626–628, 626f, 627c, 627t
presurgical evaluation, 628, 631r
MRI, 624–626
in neocortical epilepsies, 628–631, 628t, 629f, 630f
PET, 640
in preoperative workup, 731, 733r, 734f
for childhood epilepsy, 676, 678f
in Rasmussen encephalitis, 590f, 624, 639
SPECT, 641
in status epilepticus, 772, 774, 776, 780t
in surgical candidates, 731
in tuberous sclerosis, 637f–639f, 638
Neuroinflammation, 573
Neuroleptics. See Antipsychotics
Neurologic Disorders Depressive Inventory in Epilepsy, 688
Neurologists, 588
Neuronal ceroid lipofuscinosis, 579t
NeuroPace Responsive Neurostimulation System, 749–751
efficacy of, 751, 751f
implantation of, 750
mechanism of action of, 750, 751f
randomized controlled trial of, 750–751, 751f
Neuropsychological comorbidities, 682–695, 695r–696r
cognitive impairment, 682–687
health-related quality of life, 691–693
psychiatric disorders, 687–691
– anxiety disorders, 691
– depression, 687–691
psychosis, 691
Neuropsychological testing, in preoperative workup, 732
for childhood epilepsy, 676, 676f
Neurostimulation, 743–754, 754r–755r
deep brain stimulation of anterior nucleus of thalamus, 743, 746–749, 748f
devices for, 745, 744
– advantages and disadvantages of, 753
– responder rates for, 752–753
responsive, 743, 749–751, 750f, 751f
trigeminal nerve stimulation, 743, 751–752, 753f
vagus nerve stimulation, 743, 744–746, 746t, 747c
Non epileptic behavioral disorders, 715–727, 727r–729r
nonpsychogenic, 715
psychogenic (See Psychogenic nonepileptic events or episodes)
Nonsyndromic epilepsies, 589t, 590–591, 591f, 594
resolution of, 595
North American AED Pregnancy Registry, 704, 706
Obese patients, 650
Occipital epilepsy, late onset childhood, 587t
Ohtahara syndrome, 579t, 586t
EEG in, 607, 609t, 674t
treatment choices for, 674t–675t
Oligodendrogliomas, 638, 638f, 736
Oral contraceptives, interaction with antiepileptic drugs, 652, 702
Ornithine transcarbamylase deficiency, 579t
Oral alimentary seizures, 585t
Osteopenia/osteoporosis, antiepileptic drug induced, 652, 711–712, 711c
Oxcarbazepine adverse effects of, 646t
cognitive effects of, 684, 693r
efficacy and tolerability of, 643, 648
mechanism of action and metabolism of, 644t
mood-stabilizing effects of, 652
as narrow-spectrum agent, 645, 648t
in pregnancy
– pharmacokinetics of, 710, 710t
– teratogenicity of, 707c
– use in children, 666–667t
Panayiotopoulos syndrome, 586t, 624
EEG in, 674t
treatment choices for, 674t–675t
Panic disorder, 726
Paroxetine, 692c
Paroxysmal movement disorders, 715
PDR (Physicians’ Desk Reference), 802, 804r
Pediatric neurologists, 588
Pediatric patients. See Childhood epilepsy
Pentobarbital
– adverse effects of, 787t, 789
– coma induced by, 770c
– dosage of, 786t
– pharmacokinetics of, 787t
for status epilepticus, 783f, 786t–787t
– refractory, 788–789
Perampanel, 645t, 646t
– spectrum of activity of, 648t
– use in children, 666–667t
Perimenopausal transition, 700
Periodic lateralizing discharges (PLDs) on EEG, 613, 613t, 614f
Periodic patterns on EEG in critically ill and comatose patient, 609, 613, 613t, 614f
Periventricular nodular heterotopia, on MRI, 635f, 636, 636f
PET. See Positron emission tomography
Pharmacokinetics of antiepileptic drugs, intrapartum and postpartum, 709–711, 710t, 714f
Pharmacoresponsive or pharmacoresistant epilepsy, 595, 730–731, 731t, 743
Phenobarbital, 606c, 692c
adverse effects of, 646t, 785t, 802
depression, 652
as broad-spectrum agent, 645, 648t
cognitive effects of, 684, 693r
combined with valproate, 649, 649t
dosage of, 784t
drug interactions with, 652
hypersensitivity to, 650
mechanism of action and metabolism of, 644t
pharmacokinetics of, 710, 710t, 785t
in pregnancy
neurodevelopmental outcomes of, 707
pharmacokinetics of, 710t
teratogenicity of, 705c, 706f, 707t
seizures worsened by, 645
for status epilepticus, 770c, 778, 781t,
784t–785t
use in children, 668t–669t
Phenobarbital
adverse effects of, 646t, 785t, 802
during breast-feeding, 685
cognitive effects of, 684, 693r
combined with carbamazepine, 649, 649t
dosage of, 784t
drug interactions with, 652
hypersensitivity to, 650
mechanism of action and metabolism of, 644t
pharmacokinetics of, 710, 710t, 785t
in pregnancy
neurodevelopmental outcomes of, 707
pharmacokinetics of, 710t
teratogenicity of, 705c, 706f, 707t
seizures worsened by, 645
for status epilepticus, 770c, 778, 781t,
784t–785t
use in children, 668t–669t
Photic stimulation, EEG with, 601, 602f
Photic paroxysmal responses, 601, 602f
Physicians’ Desk Reference (PDR), 802, 804t
Plasmapheresis
for childhood epilepsy, 679
for status epilepticus, 788t–789t
PLDs (periodic lateralizing discharges) on EEG, 613, 613t, 614f
PNEE. See Psychogenic nonepileptic events or episodes
Polycystic ovarian syndrome, 700, 713r
Polymicrogyria, on MRI, 634–636, 634f, 635f
Positron emission tomography (PET), 623, 640, 642r, 731
18F-fluorodeoxyglucose, 623, 640, 642r
doing cortical dysplasia, 738f
in mesial temporal lobe epilepsy, 640
in neocortical epilepsies, 628t
in preoperative workup, 734, 734f
for childhood epilepsy, 676
Posttraumatic stress disorder (PTSD), 688, 726
Pregabalin
adverse effects of, 646t, 787t
weight gain, 650
dosage of, 784t
efficacy of, 648
hypersensitivity to, 650
mechanism of action and metabolism of, 644t
as narrow-spectrum agent, 645, 648t
pharmacokinetics of, 787t
in renal disease, 650
for status epilepticus, 786t–787t
use in children, 668t–669t
Pregnancy, 702–711, 713–714
antiepileptic drugs in, 652–653, 653c, 655r, 685, 686c, 702–711 (See also specific drugs)
neonatal complications of, 708–709
neurodevelopmental effects of, 685, 686c, 694r, 702–709, 709f
pharmacokinetics of, 709–711, 710t
teratogenicity of, 652, 653c, 702, 703, 703t
monotheories, 703–706, 705c, 706f, 707t
polytherapy, 706–707
effect on seizure frequency, 709
seizure risk to fetus, 709
Premature ovarian failure, 700
Presentation of seizures, 573–576, 575t, 573571
Primidone
as broad-spectrum agent, 648t
drug interactions with, 652
mechanism of action and metabolism of, 644t
pharmacokinetics in pregnancy, 710t
Profile of Mood States, 684
Progesterone
during menstrual cycle, 698, 699f
during perimenopausal transition, 700
Progesterone lozenges, for catamenial epilepsy, 699–700
Propofol
adverse effects of, 787t, 789
dosage of, 784t
pharmacokinetics of, 787t
for status epilepticus, 770c, 778t, 783f, 784t–785t
refractory, 788–789
Propranolol, interaction with antiepileptic drugs, 652
Psychiatric disorders, 687–691, 694r–696r
antiepileptic drugs in, 652
anxiety disorders, 691

S Scalp EEG monitoring, 619–620 Schizencephaly, on MRI, 633–634, 634f SCNA1 gene mutations, 576c, 589t, 596r testing for, 797–799 Seizures. See also Epilepsy age at onset of, 580, 586t–587t, 674t classification of, 571–595, 595r–597r etiologies/causes of, 571, 573, 574t, 578, 579t–580t focal, 571, 573–576, 575t, 578, 581t generalized, 571, 573–576, 575t, 578, 581t induced by antiepileptic drug withdrawal, 650 mode of onset and presentation of, 571, 573–576, 574t nonepileptic mimics of (See Psychogenic nonepileptic events or episodes) patient populations likely to be overdiagnosed with, 722 pediatric (See Childhood epilepsy) psychogenic nonepileptic, 619–620 types of, 578–580, 581t, 582t, 583t, 584t–586t unprovoked, 594

Selecting serotonin reuptake inhibitors (SSRIs)
for anxiety disorders, 691
for depression, 689–690
Self-limited epilepsy, 594–595
Sertraline, 690
Sex steroid hormones
  effects of antiepileptic drugs on, 700–701, 701t
  interactions between epilepsy, antiepileptic
drugs and, 697, 698f
Shuddering attacks, 715
Staring spells, 660c, 725
Status epilepticus, 594,
  767–792, 792r
  classification of, 767, 768t
  cryptogenic new-onset, 768, 770c, 771f
  definition of, 767, 780f
  diagnostic implication of subtypes of, 772t
  dietetic therapy for, 679, 759, 761c, 766r
  in Dravet syndrome, 576f
  EEG in, 608–613, 773–774
    continuous EEG monitoring, 618, 622r, 768,
      774, 778c, 779f
    convulsive, Mycoplasma
      pneumoniae-associated, 771f
    nonconvulsive, 775f
    periodic patterns, 609, 613, 613t, 614f–615f
    progressive sequence of changes, 608–609,
      621r
  epidemiology of, 767–768
  etiologies of, 768, 769t
  generalized convulsive, 608
    clinical features of, 768–769, 770c
    EEG in, 771f
    neuroimaging in, 772
    physiologic changes in, 769, 773f
  treatment of, 776–791, 792
    failure of second-line therapy and
      refractory status epilepticus, 783, 788–790
      first-line therapy, 776–777
      general aspects of, 776
      malignant and super-refractory status
        epilepticus, 790
      medications, 776–785, 784t–789t
      nonpharmacologic approaches, 790, 790t
      second-line therapy, 777–783
        induced by antiepileptic drug withdrawal, 650
    EEG, 773–774
    evidence and guidelines for, 772, 780t–782t,
      783f
    laboratory tests, 772–773
    lumbar puncture, 776
    neuroimaging, 772, 774, 776
    mortality due to, 791
    myoclonic, after cardiac arrest, 791
    nonconvulsive, 608, 767–768
      absence, 608
      clinical features of, 769–770, 774t, 775c
        in comatose patients, 608, 618, 622r
        continuous EEG monitoring in, 618, 622r,
          768, 778c, 779f
        diagnosis in critically ill patients, 770, 772,
          778c, 779f
        antiepileptic drug trial for, 770, 777t
        criteria for, 776t
        partial complex, 608
        prolonged, neuropathologic changes after, 791
        risk factors for, 767–768
        treatment of, 791, 792
    nonencephalitic febrile, 580t
      outcome of, 791
      peak ages for, 767
      refractory
        after cardiac arrest, 791
        definition of, 783
        incidence and predictors of, 783
        treatment of, 783, 788–790, 791
  Steroid hormones, interaction with antiepileptic
drugs, 652
  Stevens-Johnson syndrome, 649, 672, 706c
    HLA-B*1502 allele and risk for, 672, 804, 805r
    Stimulus-induced, rhythmic, periodic, or ictal
      discharges (SIRPIDs) on EEG, 613, 613t
    Stiprutio, use in children, 668t
    Stroke, 587t
      nonconvulsive status epilepticus and, 618
      with psychogenic nonepileptic events or
        episodes, 722
  Structural-metabolic epilepsies, 571, 573, 574t,
    578, 587t, 590f
  Sturge-Weber syndrome, 587t, 608t, 737, 738
    dietary therapy for, 799
Subclinical rhythmic electrographic discharges of adults (SREDA) on EEG, 608, 609t, 612f
Subcortical laminar heterotopia, on MRI, 635f, 636
Subcortical structures, 573
Subdural empyema, 580t
Subdural grid electrodes, 620
Suicidality, 688–689, 804
Surgical treatment, 730–740, 740r–742r. See also Radiosurgery
  of childhood epilepsy, 673, 676–678
  candidates for, 673, 676
  estimating potential deficits after, 676, 677
  outcome of, 677–678
  preoperative workup for, 676–677, 676f, 677f
  procedures for, 677
  cognitive effects of, 685–686, 694r, 732
  for hippocampal sclerosis, 627c
  with mesial temporal sclerosis, 735, 736f
Syncope
differentiating seizures from, 656–657, 715
neurocardiogenic, 615c–618c, 616f–618f
Temporal lobe epilepsy
  autosomal dominant lateral, 579t, 587t
  cognitive impairment in, 683
  surgery effects on, 685–686
  familial, 587t, 597r
  mesial, 588
  familial, 597r
  with hippocampal sclerosis, 587t, 625f, 626f, 627c, 627t
  magnetic resonance spectroscopy in, 640
  with mesial temporal sclerosis, 735, 736c
  MRI in, 623, 625, 626f, 626t, 627c, 627t
  positron emission tomography in, 640
  single-photon emission computed tomography in, 641
  surgical treatment of, 730, 735, 736c
  Temporal lobectomy, 730, 735
  Teratogenicity of antiepileptic drugs, 652, 655r, 702, 703–707, 703t
  monotherapies, 703–706, 705c, 706f, 707t
  polytherapy, 706–707
  Thiopental, for status epilepticus, 781t, 788–789
  Thyrotoxicosis, 600
  Tiagabine
  adverse effects of, 646t
  efficacy of, 648
  mechanism of action and metabolism of, 644t
  as narrow-spectrum agent, 645, 648t
  use in children, 669t
  TNS. See Trigeminal nerve stimulation
  Tonic seizures, 581t, 584t
  differential diagnosis of, 582t
  EEG in, 582t, 583f
  Topiramate
  adverse effects of, 646t, 787t, 804, 805r
  depression, 652
  psychosis, 691
  as broad-spectrum agent, 645, 648t
  cognitive effects of, 646t, 693r
  combined with other antiepileptic drugs, 649, 649r
  dosage of, 786t
  efficacy and tolerability of, 643, 648
  mechanism of action and metabolism of, 644t
  pharmacokinetics of, 787c
  in pregnancy, 652, 653c, 655r, 704
  teratogenicity of, 652, 653c, 704, 707t
  for status epilepticus, 786t–787t
  use in children, 670t–671t
  weight loss induced by, 650
  Tramadol, EEG abnormalities induced by, 600
  Traumatic brain injury, 580t, 587t, 603t
  nonconvulsive status epilepticus due to, 618, 778c, 779f
  with psychogenic nonepileptic events or episodes, 722
  surgical treatment of epilepsy due to, 737–738
  Tricyclic antidepressants, 690, 692c
  Trigeminal nerve stimulation (TNS), 743, 751–752, 755r
  adverse effects of, 752
  basic science and mechanism of action of, 752
  responder rate for, 752, 753f
Triphasic waves on EEG, 602, 603t, 604, 604f, 621r
Tuberculosis, 580t
Tuberous sclerosis complex, 578, 579t, 587t
dietary therapy for, 679, 759, 765r
neuroimaging in, 637–638, 637f
surgical treatment of, 737
vagus nerve stimulation in, 678
Types of seizures, 578–580, 581t, 582t, 583f
extended terminology for, 584t
637

U
UK Epilepsy and Pregnancy Register, 704
Unknown causes, epilepsy due to, 571, 573, 574t, 588t
Unverricht disease, 579t
Uremia, 600

V
VA Cooperative Geriatric Epilepsy Study, 684
Vagus nerve stimulation (VNS), 743, 744, 746,
advantages of, 753
cardiac effects of, 744
in childhood epilepsy, 593t, 678, 746
neuroimaging in, 637–638, 637f
cognitive effects of, 686–687
complications of, 678
for depression, 745
in drug-resistant epilepsy, 731
efficacy of, 745, 747c
electrode placement for, 744
ketogenic diet and, 759
parameters and programming settings for, 745, 746t
responder rate for, 752
transcutaneous, 743, 745–746
Valproate
for absence seizures with perioral myoclonia,
606c–607c
adverse effects of, 646t, 780, 785t, 802, 805r
hepatotoxicity, 780, 801c
monitoring for, 801c
polycystic ovarian syndrome, 700
weight gain, 650
during breast-feeding, 685
as broad-spectrum agent, 645, 648t
for children, 779–780
cognitive effects of, 684, 693r
combined with lamotrigine, 649, 649t, 653c
combined with phenobarbital, 649, 649t
dosage of, 784t
drug interactions with, 652
efficacy and tolerability of, 648, 654r
in hepatic disease, 650
hypersensitivity to, 650
indications for, 647
mechanism of action and metabolism of, 644t
mood-stabilizing effects of, 652
pharmacokinetics of, 785t
in pregnancy, 652–653, 685, 686c, 704, 705c
neurodevelopmental effects of, 707, 708, 709f
pharmacokinetics of, 710t
teratogenicity of, 652, 653c, 704, 705c,
706–707, 708t, 708
in status epilepticus, 770c, 775c, 778–780, 783,
785t, 784t–785t
for diagnosis of nonconvulsive status epilepticus,
777t
use in children, 670t–671t
Venlafaxine, 690
Versive seizures, 584t
Video-EEG monitoring, 598, 619–620, 622r, 731
in diagnosis of psychogenic nonepileptic events or episodes, 715, 717–720, 718t, 726, 727–729r
inductions for, 719
pitfalls of, 719–720
short-term outpatient, with activation, 719
invasive monitoring, 620
in preoperative workup, 731, 733f, 734, 739f
for childhood epilepsy, 676, 676f
scalp EEG monitoring, 619–620
for seizure confirmation in children, 657
Vigabatrin
adverse effects of, 646t, 787t, 804, 805r
depression, 652
dosage of, 786t
efficacy of, 648
for infantile spasms, 577c, 654r
mechanism of action and metabolism of, 644t
as narrow-spectrum agent, 645, 648t
pharmacokinetics of, 787t
for status epilepticus, 786t–787t
use in children, 670t–671t
Vitamin D level, antiepileptic drug effects on, 652, 711c, 712, 714r
VNS. See Vagus nerve stimulation
Vocal seizures, 585t

W
Walker-Warburg syndrome, 579t
Warfarin, interaction with antiepileptic drugs, 652
Weight changes, antiepileptic drug-induced, 650
West syndrome, 576, 579t, 586t, 590, 591f, 594.
See also Infantile spasms
classification and characterization of, 593t
dietary therapy for, 759
EEG in, 603t, 607, 609t, 674t
Wicket spikes on EEG, 607, 608, 609t, 611f
Women with epilepsy, 697, 712, 714r
antiepileptic drugs for, 652–653
during breast-feeding, 684–685, 694r, 705c
in pregnancy, 652–653, 655c, 655r, 685, 686c
tridirectional interactions between epilepsy, sex steroid hormones and, 697, 698f
bone health of, 711–712, 711c
catamenial epilepsy, 697–700
criteria for, 698
definition of, 697
patterns of, 698, 699f
treatment options for, 698–700
contraception for, 702
during perimenopause and menopause, 700
pregnancy in, 702–711 (See also Pregnancy)
reproductive function of, 700–702
antiepileptic drug effects on reproductive hormones, 700–701, 701t
fertility and childbirth rates, 701–702

Z
Zonisamide
adverse effects of, 646t
psychosis, 691
teratogenicity, 707t
as broad-spectrum agent, 645, 648t
cognitive effects of, 684, 694r
combined with other antiepileptic drugs, 649, 649t
efficacy and tolerability of, 643, 648
mechanism of action and metabolism of, 645t
use in children, 670t–671t
weight loss induced by, 650